

NLC inspiration journey Stockholm

September 28 – 30, 2022

Participants and their organizations (13 persons)

NLC - the healthtech venture builder

<http://www.nlc.health>

NLC is the European healthtech venture builder, bringing science-based healthtech inventions to life. The company was founded in 2014 based on one simple observation: due to market complexities and fragmentation at least 95 per cent of healthtech inventions never reach the patient and the market, regardless of their relevance or brilliance. We bring together the best tech, the best people, and the best capital to build life-changing healthtech ventures. Our process starts at the academic institutions and corporates, with which we collaborate to develop ventures based on their inventions and IP. NLC (co)founds the new venture, attracts the team and supports the venture as active shareholder for multiple years, until we can transfer our share to a party suitable to boost the next growth phase of the venture.

Biography

Julie Yang

Venture Support Expert

Julie joined NLC in September 2021 as Venture Support Officer. She is dedicated to improving the healthcare industry by implementing data-driven, evidence-based solutions and seeking innovations in HealthTech. She holds a joint degree of MS in Agro-biomedical Science from National Taiwan University, Tsukuba University, Université de Bordeaux and an EMBA from Quantic School Of Business and Technology. Julie is passionate about supporting ventures to bring science to life and innovations to patients.



Marcos Vega-Hazas Marti

Venture Support Expert

Marcos holds a B.Sc. (Hons) in Biochemistry from King's College London. He has a background in life sciences, having worked both at biotech startups and with global pharma companies as a market access consultant. At NLC, Marcos is responsible for building the market development services, helping ventures bring their products into the market more successfully.



Michiel Mussies

Lead Venture Support

Driven, internationally oriented generalist aiming at having a positive impact for people and society. As lead Venture Support, he is providing services to scale NLC's ventures to bring innovation to healthcare and to improve people's lives. He holds an MA in International Relations from the University of Groningen and an MBA from INSEAD.

Taco van der Feltz

Venture Partner

Entrepreneur in Life Sciences, international experience in commerce, R&D, leadership consulting and venture building. - Led the market development and introduction of first in class pharmaceutical products in multiple countries. - Led the turnaround of the corporate marketing strategy of a global Medical Nutrition and Devices company. - Successfully advised life sciences companies on leadership and recruited hundreds of executives and non-executive directors for companies ranging from global top five healthcare companies to small (venture capital backed) startups. - Was responsible for and supported the founding and growth of dozens of healthtech startups. - Degrees Msc. Biology & Medical Doctor.



Christine Ammon

Venture Support Expert

Christine joined NLC in February 2022 as a biomedical sciences master's student with a management specialisation and is a part of the Venture Support. During her time at the Leiden University Medical Centre conducting research, Christine came to recognise that healthcare needs innovation and entrepreneurship to advance. She is dedicated to creating a lasting, positive impact on individuals and making healthcare accessible to all. Impact-driven, focused and a team player, she is excited to bring science to life.



NLCs ventures

AIDO

<https://aido.health/>

AIDO is a medical device start-up that developed a unique technology to motorize and control the insertion of instruments into the working channel of flexible endoscopes. We aim to make the AIDO platform a key technology to move surgery to less invasive and more cost-effective endoscopic procedures and be the companion for advanced users to push the boundaries of interventional endoscopy.

Biography

Helena Grinberg-Rashi

CEO

Helena is a life-sciences executive with more than 15 years of experience in medical devices, pharmaceuticals, and biotechnology ventures. Prior to joining AIDO, she held several leading roles (CEO/COO/VP) in health-tech startups. Helena is an expert in clinical development, and global regulations, with a proven track record of leading the product development process from concept to clinical studies worldwide, successful regulatory submissions in Europe and in the USA, and bringing innovative products to the global market. Helena is the founder and CEO of Titania Technologies, a Netherlands-based strategic consultancy firm. She also serves as a mentor and an advisor for various health-tech start-ups. Helena earned her Ph.D. in molecular medicine and human genetics from Tel Aviv University, Israel (2006) and her MBA from the Richman University (IDC) Hertzlia, Israel (2017).



Bilihome

<https://www.bilihome.org/>

Biography

Margret Heunerbein

Implant Preservation Devices BV

<https://ipd.health>

IPD, The solution for prosthetic and metal implant infections using non-contact induction implant heating. One of the biggest problems of a total joint (e.g., hip/knee) replacement is a prosthetic joint infection (PJI), counting for almost 60.000 cases per year. Treatment is highly invasive for the patient and has a high impact on health care spending. To remove the bacterial biofilm is very difficult with recurrent infection and morbidity as a risk. By using antibacterial implant heating the bacterial biofilm can easily be removed with a 1.5-minute treatment intra operatively, using induction, which removes the bacterial colonization from the implant. The heating reaches areas, where irrigation and antibiotics cannot. A one-time operative, highly cost saving, procedure with an improved patient outcome. Key words Unique, Innovative, changing landscape of treating joint replacement infections, Worldwide well-known inventor. Broad experienced team. 70% predicted health care cost reduction It's new, it's unique, it improves quality of life for this patient group, it saves healthcare cost

Biography

Richard van de Wateringen

CEO

CEO Implant Preservation Devices at NLC. 30+ years of experience in Medical Devices, with a focus on Orthopaedics. Additional experience in Wound Care, Ostomy Care and Dental care. Has held senior management roles in a number of leading Orthopaedic and Medical Device companies for the last 25 years. Launched groundbreaking Orthopaedic implant devices in major markets and developed Orthopaedic businesses in emerging markets.



LUMABS BV

<http://www.lumabs.com>

Next generation bioluminescence-based homogenous immunoassay platform supporting quantitative, highly sensitive and rapid one-step biomolecule quantification in complex human samples. Bioluminescent-based homogeneous sensors that display a change in color upon analyte binding show great promise for measurements in complex media such as blood plasma, as minimal sample pretreatment is required. Unlike fluorescence-based methods, bioluminescent sensors do not need external excitation, thus eliminating issues associated with autofluorescence or light scattering. LUMABS BV founder has developed RAPPID (Ratiometric Plug-and-Play ImmunoDiagnostics), a mix-and-measure immunoassay platform based on the reconstitution of antibody-conjugated split NanoLuc luciferases. The platform is highly modular, as it entails monoclonal antibodies and conjugation through a protein adaptor. The straightforward development of a RAPPID assay enables the easy exchange of antibodies and hence screening for the best antibody pair and optimal sensor. Furthermore, the RAPPID platform has a high intrinsic maximal change in emission ratio and a robust ratiometric light output, enabled by the introduction of a green-emitting calibrator luciferase, facilitating the accurate detection of biomarkers in the picomolar to nanomolar range. The ratiometric nature of the RAPPID assay makes this platform an attractive diagnostic development tool to detect challenging biomarkers. Having demonstrated our technology and raised our initial seed capital, LUMABS BV is currently looking to expand the breadth of antibodies/antigens for which we have developed corresponding LUMABS and RAPPID reagents. Therefore, we encourage potential partners who are developing novel immunoassays (such as therapeutic antibodies), or already have them in the clinic and/or market already, and have a need for updated bioanalysis tools (such as moving from a Heterogeneous ELISA format to a Homogeneous one) to gain a competitive edge in the marketplace, to contact us to discuss their needs and the solutions LUMABS BV Technological Platform can offer.

Biography

Antonio Soares

CEO

Results-driven international Medical Devices Executive and Entrepreneur with a proven track record in strategy development and implementation, business development, commercial analysis and general management roles at both corporate and business unit levels at top-tier firms. Unique background of experience in both global corporations and deep tech startups. Experience in setting up/supporting technology platform-based companies up to successful exits in the Life Science, Medical Device and In-vitro Diagnostic sectors. Successfully supported non-dilutive funding strategies resulting in 2,5-10M€ investments through European funding. Coached and mentored over 30+ startups throughout Europe.



MLA Diagnostics BV

<http://www.mladx.com>

MLA Diagnostics BV (MLA Dx) is a startup established in 2019 around an invention of Maastricht University, The Netherlands. The company focuses on DNA methylation (epigenetic) biomarkers in oncology, currently working on its first product, a prognostic biomarker test for melanoma. MLA Dx has an extensive network of scientific partners both in The Netherlands and abroad and is further supported by an extensive expert network. MLA Dx is based in Maastricht, the Netherlands and has a team of 5 working in product development, quality & regulatory, operations and business development. The company is well-funded currently and plans to finalise its first product in 2023. The company is also fundraising (series A of 2 M) to complete product development and obtain CE mark.

Persuasive BV

www.persuasivedx.com

PERSUASIVE BV is a startup established in 2019 around an invention of Utrecht University, The Netherlands. The company focuses on the early Diagnostics optic application of extracellular vesicle (EV) biomarkers in cardiovascular disease. Currently PERSUASIVE is working on its first product, an integrated EV isolation and biomarker testing workflow for stable angina (also called chronic coronary syndrome). PERSUASIVE BV has an extensive network of scientific partners both in The Netherlands and abroad and is further supported by an extensive expert network from the diagnostic / routine laboratory area. PERSUASIVE BV is based in Utrecht, the Netherlands and has a team of 5 working in product development, quality & regulatory, operations and business development. The company is plans to finalise its first product in 2023. The company is also fundraising (seed round of 0,5 - 1 M) to boost product development.

Biography

Egbert Smit

CEO MLA Diagnostics
CEO Persuasive

Egbert Smit is an experienced serial entrepreneur with extensive experience in leading health-tech startups. Over the last 10-15 years Egbert has worked in organisations in the field of biomarker R&D and molecular diagnostics primarily in cardiovascular disease and oncology. Egbert holds degrees in life sciences / molecular biology (MSc + PhD) and business administration (MBA).



Daphne Gengler

Myotact

<http://www.myotact.com>

Myotact is a medical device for restore mobility and improve the rehabilitation of people who have lost the use of their limbs.

Biography

Maxime Cavrois

CEO

With a very good knowledge of the MedTech start-up environment, my goal is to develop new disruptive solutions from scratch. With now more than 12 years of experience in the healthcare sector, I am convinced by the new solutions intended to improve the daily life of doctors and patients. I am committed to finding the best deeptech solutions to help patients, doctors and hospitals.



Facilitation

VoyEdge

<http://www.voyedge.nl>

Over the years, VoyEdge has developed, organized and facilitated more than 130 inspiration and innovation journeys with more than 2000 participants to Europe, North- and South America, Asia, Africa and the Middle East. Focus of VoyEdge is always on strong programs - tailor made to the needs of the participants - and on guiding the participants and the delegation as a whole to translate the gained insights into their strategy and day-to-day operations.

Biography

Rosalie Urselmann

Owner

VoyEdge has been set up by Rosalie Urselmann. Before VoyEdge Rosalie has gained more than 10 years of business experience with several roles and activities in both companies as well as in government organizations. In university she already started with the organization of study tours and has been able to keep on doing this during her jobs at KPN, Xantic and the Netherlands Foreign Investment Agency in San Francisco. In 2005 she decided to quit her other activities and fully focus on organizing high quality international business study trips for delegations from industry, entrepreneurs, government organizations and research- and educational institutes. Because of a growing need from these delegations, she started VoyEdge in 2007. Rosalie has lived, studied and worked in Silicon Valley for several years. Her knowledge about and her network in Silicon Valley are now a strong edge in organizing inspiration tours to this global Center of Excellence. Rosalie holds an MSc degree in Industrial Engineering and Management from the University of Twente (Netherlands).

